A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide.

Molecules

State Key Laboratory of NBC Protection for Civilian, Beijing 102205, China.

Published: January 2023

Linaclotide is a 14-amino acid residue peptide approved by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C), which activates guanylate cyclase C to accelerate intestinal transit. Here we show a new method for the synthesis of linaclotide through the completely selective formation of three disulfide bonds in satisfactory overall yields via mild oxidation reactions of the solid phase and liquid phase, using 4-methoxytrityl (Mmt), diphenylmethyl (Dpm) and 2-nitrobenzyl (O-NBn) protecting groups of cysteine as substrate, respectively.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9919235PMC
http://dx.doi.org/10.3390/molecules28031007DOI Listing

Publication Analysis

Top Keywords

regioselective synthesis
4
synthesis cysteine-rich
4
cysteine-rich peptide
4
peptide linaclotide
4
linaclotide linaclotide
4
linaclotide 14-amino
4
14-amino acid
4
acid residue
4
residue peptide
4
peptide approved
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!